{
    "clinical_study": {
        "@rank": "72273", 
        "arm_group": [
            {
                "arm_group_label": "RDC5 dose level 1", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of RDC5"
            }, 
            {
                "arm_group_label": "RDC5 dose level 2", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of RDC5"
            }, 
            {
                "arm_group_label": "RDC5 dose level 3", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of RDC5"
            }, 
            {
                "arm_group_label": "RDC5 dose level 4", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of RDC5"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to characterise the pharmacokinetics, safety and tolerability\n      of RDC5 given as a single dose to healthy volunteers at a number of different dose levels"
        }, 
        "brief_title": "A Phase 1 Study of the Pharmacokinetics of RDC5 in Healthy Volunteers", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "This is an open-label, randomised, single dose, 3-way crossover study to characterise and\n      compare the PK, safety and tolerability of RDC5 in 15 healthy male volunteers. Eligible\n      subjects will undergo 3 Treatment Periods, each separated by a washout period at least 14\n      days.  Subjects will receive a single dose of RDC5 during each of the three Treatment\n      Periods in line with their randomized treatment sequence.  A total of 4 dose levels will be\n      evaluated within the study, though each subject will only receive 3 doses.  A Data Review\n      Team (DRT) will review the pharmacokinetic (PK) data from Treatment Periods 1 and 2 and\n      select the doses to be evaluated in Treatment Periods 2 and 3. Subjects will return for a\n      follow visit 21 days after the last dose of RDC5."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing to use effective method of contraception\n\n          -  Non smoker or ex-smoker within the previous 6 months\n\n        Exclusion Criteria:\n\n          -  History or presence of any clinically significant findings upon screening\n\n          -  Participation in a New Chemical Entity clinical study within the previous 124 days or\n             a marketed drug clinical study within the previous 93 days\n\n          -  Positive result for human immunodeficiency virus (HIV) and/or hepatitis B or C test\n\n          -  Positive result for urine alcohol and drug screen\n\n          -  Blood donation \u2265 450 mL in the previous 12 weeks\n\n          -  Receipt of prescription medicines and/or St John's Wort in the previous 2 weeks"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016742", 
            "org_study_id": "RDC5-1-01", 
            "secondary_id": "2013-003335-29"
        }, 
        "intervention": {
            "arm_group_label": [
                "RDC5 dose level 1", 
                "RDC5 dose level 2", 
                "RDC5 dose level 3", 
                "RDC5 dose level 4"
            ], 
            "intervention_name": "RDC5", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacokinetics", 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Merthyr Tydfil", 
                    "country": "United Kingdom", 
                    "zip": "CF48 4DR"
                }, 
                "name": "Simbec Research Ltd"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I, Open-label, Randomised, 3-way Crossover Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of RDC5 Given as a Single Dose to Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Simbec Research", 
            "last_name": "Girish Sharma", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the concentration-time curve from time 0 to infinity (AUC0-inf) for the whole blood concentration of RDC5", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 days post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016742"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC from time 0 to time of last observed concentration (AUC0-t)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 days post dose"
            }, 
            {
                "measure": "Maximum observed concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 days post dose"
            }, 
            {
                "measure": "Time at which Cmax occurred (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 days post dose"
            }, 
            {
                "measure": "Elimination half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 days post dose"
            }, 
            {
                "measure": "Terminal phase elimination rate constant (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 days post dose"
            }, 
            {
                "measure": "Apparent volume of distribution (Vd/F)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 days post dose"
            }, 
            {
                "measure": "Apparent oral clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 days post dose"
            }, 
            {
                "measure": "Number (%) healthy volunteers with treatment emergent adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "10 weeks"
            }
        ], 
        "source": "Chronos Therapeutics Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chronos Therapeutics Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}